|
CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer. |
|
|
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi |
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer; Curevac; ESSA (Inst); Janssen Oncology (Inst); Orion; Sanofi (Inst) |
Travel, Accommodations, Expenses - Janssen; MSD |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi |
Research Funding - Janssen Oncology (Inst) |
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - ECOM Medical |
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Genentech; Novartis; Pfizer |
Speakers' Bureau - Amgen; Astellas Medivation; AstraZeneca; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Exelixis; Genentech/Roche; Janssen; Merck; Novartis; Pfizer; Sanofi; Seattle Genetics/Astellas; Seattle Genetics/Astellas |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Epizyme (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Macrogenics (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Astellas Medivation; AstraZeneca; Bayer; Eisai; Exelixis; Genentech; Janssen; Novartis; Pfizer; Prometheus |
|
|
No Relationships to Disclose |
|
Juan Carlos Vazquez Limon |
Honoraria - AstraZeneca; Bristol-Myers Squibb |
Consulting or Advisory Role - AstraZeneca; Roche |
Research Funding - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis |
Travel, Accommodations, Expenses - Asofarma; AstraZeneca; Pfizer |
(OPTIONAL) Uncompensated Relationships - Roche |
|
Héctor Manuel Sánchez López |
No Relationships to Disclose |
|
|
Honoraria - Astellas Scientific and Medical Affairs Inc |
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Dendreon; Merck; Pfizer |
|
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst) |
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc |
|
|
Employment - Connected Medical Solutions (I) |
Leadership - Connected Medical Solutions (I) |
Stock and Other Ownership Interests - Connected Medical Solutions (I); Imagion Biosystems |
Consulting or Advisory Role - Imagion Biosystems |
Research Funding - Astellas Pharma |
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Myovant Sciences; Pfizer; Sanofi |
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Myovant Sciences; Pfizer; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sanofi (Inst) |
|
|
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME |
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma |
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst) |
Expert Testimony - Celgene; sanofi |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Genomic Health; Jounce Therapeutics; Pfizer/EMD Serono; Sanofi |
Speakers' Bureau - AstraZeneca; Dendreon; Genentech/Roche; Genomic Health; Merck; Sanofi |
Research Funding - Janssen Oncology |
Travel, Accommodations, Expenses - Genentech/Roche |